Juraj Prejac

6PUBLICATIONS
35CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 26, 2026
Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach.

|May 27, 2026
Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation.

|May 04, 2026
Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape.

|Mar 28, 2026
Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation.

Zeljka Belosic Halle, Vedran Tomasic, Alen Biscanin

|Sep 14, 2024
Salivary Interleukin-13 and Transforming Growth Factor Beta as Potential Biomarkers of Cancer Cachexia.

Borislav Belev, Ivan Vičić, Filip Sedlić

|Oct 01, 2022
The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.

Juraj Prejac, Dora Tomek Hamzić, Nikša Librenjak

Pageof 1

Frequent Collaborators

4 joint publications

Marin Golčic

1 joint publications

Ivan Vičić

1 joint publications

Davorin Herceg

1 joint publications

Ana Kulić